WHO – 4th Fair Pricing Forum

By João L. Carapinha

February 2, 2024

Introduction to Fair Pricing

The 4th Fair Pricing Forum is a major event that tackles the big issues in healthcare: how to make drugs and treatments affordable and accessible for everyone. Let’s jump into some key sessions and what they mean in plain terms.

Day 1: Open and Transparent Markets

First, there’s a lot of talk about making the healthcare market more open and transparent. This is about letting everyone know how drugs are priced and why. But, the big question is, has making things more transparent actually made drugs cheaper for people? Sometimes, when governments try to make things clearer, it doesn’t always lead to lower prices. At Syenza, we’ve seen a lot of this and wonder if these efforts are really working as intended.

Another hot topic is about “managed entry agreements.” This is a fancy way of saying that some drugs get to the market with special deals, so they can be used faster based on real-world data. But collecting this data is tough, especially in countries that don’t have the tech or money to do it well. Are governments really on board with these deals, or are they just a new trend that’s hard to put into practice?

Day 2: “Fair” Profit for Innovators

On the second day, there’s a big discussion about what counts as a “fair” profit for drug companies. It’s tricky. How much profit is okay, and does it change based on the drug or the country? This session is crucial because it touches on the balance between making money and making sure treatments are affordable.

One session focuses on the high costs of medicines for rare diseases. These costs aren’t just about money; they affect people’s lives deeply. We’re eager to see real examples of how to handle this issue.

Day 3: Health Technology Assessment toward Fair Pricing

Day three looks at the challenges of using Health Technology Assessment (HTA) in poorer countries. HTA is about figuring out the value of new drugs or treatments. But often, this comes down to using the country’s wealth as a measure, which doesn’t seem fair. Are there better ways to do this that don’t just boil down to how much money a place has?

Conclusion

Throughout the forum, there’s a lot of focus on government actions and policies. But there’s not enough talk about what companies are doing on their own to solve these problems. There seems to be a missed opportunity to look at how the private sector can help fix the issue of drug pricing without waiting for government intervention.

In short, the Fair Pricing Forum is tackling some of the biggest challenges in making healthcare accessible to everyone. But the real test will be moving from talking about these problems to actually doing something about them. We need to think about both the role of governments and companies in making treatments affordable and accessible. It’s not just about finding faults but working together for real solutions.

Reference url

Recent Posts

AAP childhood obesity guidelines
     

Caution Advised: Conflicts in AAP Childhood Obesity Guidelines

Are childhood obesity guidelines driving us toward conflict? 🌍 The recent AAP guidelines suggest weight loss medications for children as young as eight, but undisclosed financial ties to drug manufacturers raise serious questions about credibility.

In this article, we dive into the implications of these conflicts and the evidence gaps surrounding pharmaceutical interventions in pediatric care. Transparency and trust are crucial when it comes to the health of our children—let’s explore what needs to change.

Read more to find out how these guidelines could impact families, clinicians, and healthcare policy.

#SyenzaNews #HealthcareInnovation #HealthcarePolicy

implantable glucose device
         

T1 Diabetes Care with an Implantable Glucose Device

🚀 Are we on the brink of a diabetes breakthrough?

A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight.

Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look!

#SyenzaNews #HealthTech #HealthEconomics #Innovation

federated learning governance
      

Federated Learning Governance in Healthcare: A Framework for Ethical and Effective Implementation

🔍 Have you considered how federated learning governance can revolutionize healthcare data collaboration?

In our latest article, we explore the critical principles of federated learning governance, emphasizing its role in managing decentralized health data while protecting patient privacy and improving research quality. Learn about the actionable strategies healthcare organizations can implement to navigate the unique challenges that come with this innovative approach.

Dive deeper into the world of federated learning in healthcare and unlock its potential for ethical and effective data use!

#SyenzaNews #AIinHealthcare #DigitalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.